Genmab presents "encouraging" data for cervical cancer candidate

During the annual European Society for Medical Oncology conference (ESMO), Genmab and partner have released results for the therapy tisotumab vedotin, for which the company is seeking priority review status.

Photo: Joost Melis / Genmab / PR

Genmab and its partner Seagen have presented interim data from a study of the drug tisotumab vedotin in combination therapy with the treatment of recurrent or metastatic cervical cancer.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs